MENA Ethosuximide Market Share, Size, Trends, Analysis: By Product: Capsule, Tablet, Syrup, Others; By Procurement: Annual Procurement (Government Agencies, Public Hospitals), Private Procurement (Drug Stores, Private Hospitals); Regional Analysis; Competitive Landscape; Key Trends and Developments in the Market; 2024-2032

MENA Ethosuximide Market Outlook

The MENA ethosuximide market size is expected to grow at a CAGR of 3.30% between 2024 and 2032. The market is being driven by the increasing prevalence of epilepsy and growing healthcare infrastructure and expenditure.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

Ethosuximide is an anticonvulsant drug which is used to regulate absence (petit mal) seizures in epileptic patients. The compound is obtained from succinic acid and operates by reducing instances of abnormal electrical activity in the patient’s brain. In absence seizures, the patient experiences a short loss of awareness during which there is lack of response but may continue to blink eyes or stare. 

• The rapid growth of the healthcare sector across the emerging economies of the Middle East North Africa (MENA) region is driving the MENA ethosuximide market. Growing efforts by the governments in the region aimed towards reducing economic vulnerability are heightening the healthcare expenditure.

• The increasing prevalence of absence seizures, particularly among children between the ages of 2 years and 12 years, is further escalating the demand for ethosuximide across the healthcare units.

• The surging applications of smart and modern technologies and penetration of internet of things (IoT) and artificial intelligence, are improving the diagnostics and treatment infrastructure. Hence, advancements in neuroscience-related facilities across the region are expected to propel the usage of ethosuximide.

• The growing research and development activities aimed towards improving the quality of medication, reducing the injuries associated with epileptic seizures, and developing minimally invasive diagnostic and treatment procedures, are likely to provide impetus to the MENA ethosuximide market in the forecast period.

Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on product, the market is segmented into capsule, tablet, and syrup, among others. On the basis of procurement, the market is classified into annual procurement (government agencies, public hospitals) and private procurement (drug stores, private hospitals). By country, the market for ethosuximide in MENA is divided into Saudi Arabia, United Arab Emirates, Iran, Egypt, Morocco, Qatar, Kuwait, and Oman, among others.  

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the MENA ethosuximide market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.

• Pfizer Ltd

• Essential Pharma Ltd

• Qatar Pharmaceuticals Industries

• Delta Pharma

• Others

Market Share by Product

The capsule segment, based on product, accounts for a healthy share of the MENA ethosuximide market due to its ability to be combined with other components that can help in the treatment. A capsule can contain ethosuximide along with polyethylene glycol, gelatin, and sorbitol, among other ingredients useful for treating epilepsy. Ethosuximide capsules are capable of suppressing the paroxysmal three cycle per second spike which comes along with lapses of consciousness during absence seizures. Meanwhile, the syrup segment is expected to witness a positive growth in the forecast period, owing to the faster rate of absorption, greater optimisation, easy digestibility, and suitability for children. 

Market Share by Procurement

Based on procurement, private procurement (drug stores, private hospitals) segment occupies a growing share of the MENA ethosuximide market due to the rapidly improving private healthcare network in the region. As absence seizures are relatively lesser known and can be difficult to notice and diagnose, potential patients are likelier to belong to higher income groups and visit private hospitals where the quality of treatment is considered to be higher. Although the hospital infrastructure varies significantly between the different countries in the region, efforts to encourage private participation in the healthcare sector, to improve the quality of care while reducing burden on the government, can be witnessed throughout the region. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Pfizer Ltd is a leading pharmaceutical company which produces research-based pharmaceutical and biopharmaceutical products. It is also one of the leading manufacturers of vaccines, catering to the treatment demands of various chronic conditions, by innovating to develop new products and formulations. The company was established in the year 1952 and is headquartered in Tadworth, United Kingdom.

Essential Pharma Ltd produces and ensures sustainable supply of low-volume clinically-superior, and well established pharmaceutical products. The company strives to help patients get access to good quality therapeutics and medicines that can help them manage their healthcare concerns. The company was founded in the year 2011 and is currently headquartered in Surrey, United Kingdom.  

Qatar Pharmaceuticals Industries is a pharmaceutical company which manufactures and sells generic and branded drugs aimed towards improving the health of patients suffering from chronic conditions. The product portfolio of this company includes softgels, liquids, tablets, and capsules, among others. Qatar Pharmaceuticals Industries was founded in 2008 and is headquartered in Doha, Qatar. 

Other market players include Delta Pharma, among others.

Key Highlights of the Report

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.